Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

actavis new zealand limited - docusate sodium 50.69mg equivalent to 50 mg anhydrous;  ; sennosides 8mg equivalent to 11.27 mg of raw material of potency 71% - coated tablet - active: docusate sodium 50.69mg equivalent to 50 mg anhydrous   sennosides 8mg equivalent to 11.27 mg of raw material of potency 71% excipient: calcium phosphate colloidal silicon dioxide magnesium stearate maltodextrin

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docusate sodium 50mg (50mg anhydrous = 50.69mg docusate sodium); sennosides 8mg equivalent to 11.27 mg standard raw material of 71% potency.;   - film coated tablet - active: docusate sodium 50mg (50mg anhydrous = 50.69mg docusate sodium) sennosides 8mg equivalent to 11.27 mg standard raw material of 71% potency.   excipient: calcium hydrogen phosphate dihydrate calcium phosphate carnauba wax colloidal silicon dioxide magnesium stearate maize starch maltodextrin microcrystalline cellulose opadry brown oy-26502 - the treatment of constipation.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - glycerol, quantity: 2.8 g - suppository - excipient ingredients: gelatin; purified water - laxative suppository treatment for acute constipation relief

India - Kiingereza - Central Drugs Standard Control Organization

gsk - clindamycin - gel - 1%w/w( benzoyl peroxide ph. eur. eq to anhydrous benzoy peroxide 5% w/w) - 10 gm tube

Marekani - Kiingereza - NLM (National Library of Medicine)

manna omni international incorporated - camphor leaf oil (unii: 51d0rgy52v) (camphor leaf oil - unii:51d0rgy52v), 7-aminodesacetoxycephalosporanic acid (unii: anm3msm8tn) (7-aminodesacetoxycephalosporanic acid - unii:anm3msm8tn), menthol, unspecified form (unii: l7t10eip3a) (menthol, unspecified form - unii:l7t10eip3a), methyl salicylate 2-ethylbutyrate (unii: j8d9175q0g) (methyl salicylate 2-ethylbutyrate - unii:j8d9175q0g), peppermint oil (unii: av092ku4jh) (peppermint - unii:v95r5kmy2b) - directions: clean the affected area, then apply to pain area. rub or massage the area continuously until the lotion has been fully absorbed into the area. use only as directed. avoid contact with the eyes and mucous membranes. do not apply to open wounds, damaged or very sensitive skin. test on a small area before use. do not use in combination with other external analgesic products. do not bandage tightly or cover with any type of wrap, except clothing. if condition worsens, or persists for more than seven days, discontinue use and consult a physician. the purpose of our pain relieving lotion is to provide temporary relief of minor aches and pains, arthritiis pain, backache, muscle aches and strains. for the temporary relief of minor aches and pains, arthritis pain, backache,muscle vstrains and sprains. make sure to clean the affected area then apply lotion and rub into the skin until it absorbs.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rocuronium bromide, quantity: 100 mg - injection, solution - excipient ingredients: acetic acid; sodium hydroxide; sodium chloride; water for injections; sodium acetate trihydrate - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. rocuronium is also indicated as an adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rocuronium bromide, quantity: 50 mg - injection, solution - excipient ingredients: sodium hydroxide; acetic acid; water for injections; sodium acetate trihydrate; sodium chloride - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. rocuronium is also indicated as an adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

dch auriga singapore - ropivacaine hcl - injection - 2 mg/ml - ropivacaine hcl 2 mg/ml

Singapoo - Kiingereza - HSA (Health Sciences Authority)

dch auriga singapore - ropivacaine hcl - injection - 10 mg/ml - ropivacaine hcl 10 mg/ml

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).